Program 6th Norwegian Myeloma Workshop 2026
Thursday 28th of May
12:00 - 13:00 Lunch
13:00 – 13:10 Opening
Tobias S. Slørdahl & Fredrik Schjesvold
13:10 – 13:30 The Vaccine Study in Central Norway
Synne Stokke Tryggestad PhD, St. Olavs hospital/NTNU
13:30 – 13:50 IFITM1 - A new marker for malignant plasma cells
Henning Øfsteng, MD, St. Olavs hospital
13:50 – 14:10 Immune responses in the TG01-study
Else Marit Inderberg,PhD, Section of Cellular Therapy, OUH
14:10 – 14:30 Infections and other complications associated with BCMA-targeted therapies at Oslo University Hospital
Josephine Krieger, Medical student, Oslo Myeloma Center
14:30 – 15:00 Break
15:00 – 15:20 Optical single-cell profiling of multiple myeloma
Nora Yttri, NTNU
15:20 – 15:40 Characterization of the myeloma immune environment by scRNA-seq
Kristin Roseth Aass, PhD, NTNU
15:40 – 16:00 From the Gut to the Bone Marrow: Microbiota and Treatment Outcome in Newly Diagnosed Myeloma
Pegah Abdollahi, PhD, Oslo Myeloma Center
16:00 – 16:30 Break
16:30 – 16:50 Infection incidence and microbiological pattern in Norwegian myeloma patients
Juni Songe Paulsen MD, St. Olavs hospital/NTNU
16:50 – 17:10 The Impact study – analysing the microenvironment after BCMA-directed treatment
Jakob Nordberg Nørgaard, MD PhD, Oslo Myeloma Center
17:10 – 17:30 The Isolde study
Frida Bugge Askeland, MD PhD-student, Oslo Myeloma Center
18:00 Dinner
Friday 29th of May
08:45 – 08:50 Opening
08:50 – 09:10 Why does obesity increase multiple myeloma risk? The immune connection.
Therese Standal PhD, NTNU
09:10 – 09:30 The NIMMS Study – Survival and adverse events in the Norwegian teclistamab cohort
Anders Sangesland MD, St.Olavs hospital/NTNU
09:30 – 09:50 Treating with higher lenalidomide doses in the REST study
Hedda Monsen, Medical student, Oslo Myeloma Center
09:50 - 10:10 Break
10:10 - 10:30 Targeting myeloma with T-cell receptors
Johanna Olweus, MD PhD, Experimental Immunotherapy Group, OUH
10:30 – 10:40 Causes of early death in Norway
Sunniva Cook/Cathrine Dyrendahl, stud.med. St. Olavs hospital/NTNU
10:40 – 10:50 Barriers to autologous stem cell transplantation as first-line treatment in age-eligible multiple myeloma patients in central Norway.
Benjamin Wahl/Henrik Laukli, stud.med. St. Olavs hospital/NTNU
10:50 – 11:15 Bortezomib dosing in the REMNANT trial
Lars Henrik Hamnvik, MD PhD student, Oslo Myeloma Center
11:15 – 11:30 Break
11:30 – 12:00 Ongoing and upcoming clinical trials in Norway
NMSG and industry trials – Fredrik Schjesvold, Oslo Myeloma Center
12:00 – 12:15 Discussions on cooperation and conclusions
12:15 Lunch and goodbye